We are live on
!
Find out more
Neuberger Berman Group Portfolio holdings
AUM
$150B
1-Year Est. Return
40.08%
This Fund
S&P 500
This Quarter
Est. Return
+22.49%
1 Year Est. Return
+40.08%
3 Year Est. Return
+113.08%
5 Year Est. Return
+141.06%
10 Year Est. Return
+565.41%
AUM
$150B
AUM Growth
+$18.9B
(+14%)
Cap. Flow
+$836M
Cap. Flow
% of AUM
0.56%
Top 10 Holdings %
Top 10 Hldgs %
22.99%
Holding
2,421
New
260
Increased
1,156
Reduced
848
Closed
81
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$463M |
| 2 |
Apple
AAPL
|
+$418M |
| 3 |
SPCX
SpaceX
SPCX
|
+$361M |
| 4 |
NVIDIA
NVDA
|
+$291M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$285M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$428M |
| 2 |
Microsoft
MSFT
|
+$314M |
| 3 |
Boston Scientific
BSX
|
+$269M |
| 4 |
Teradyne
TER
|
+$249M |
| 5 |
T-Mobile US
TMUS
|
+$246M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.74% |
| 2 | Financials | 12.29% |
| 3 | Industrials | 12.09% |
| 4 | Healthcare | 8.91% |
| 5 | Consumer Discretionary | 8.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2276
Altimmune
ALT
$665M
| $56.7K | ﹤0.01% |
+18,664
| New | +$55.7K |
|
2277
Atea Pharmaceuticals
AVIR
$468M
| $56.2K | ﹤0.01% |
+12,077
| New | +$60.1K |
|
2278
Allogene Therapeutics
ALLO
$681M
| $55.8K | ﹤0.01% |
26,835
+12,010
| +81% | +$26.4K |
|
2279
Evolent Health
EVH
$488M
| $55.2K | ﹤0.01% |
+10,177
| New | +$39K |
|
2280
B&G Foods
BGS
$267M
| $53.9K | ﹤0.01% |
13,545
+265
| +2% | +$1.23K |
|
2281
Hyliion Holdings
HYLN
$659M
| $52.8K | ﹤0.01% |
10,136
-290
| -3% | -$1.21K |
|
2282
Ironwood Pharmaceuticals
IRWD
$704M
| $52.4K | ﹤0.01% |
12,448
-62
| -0.5% | -$239 |
|
2283
Eledon Pharmaceuticals
ELDN
$245M
| $52.2K | ﹤0.01% |
+13,246
| New | +$48.2K |
|
2284
Perspective Therapeutics
CATX
$357M
| $52.1K | ﹤0.01% |
+15,284
| New | +$57.7K |
|
2285
James River Group Holdings
JRVR
$192M
| $51.7K | ﹤0.01% |
+11,754
| New | +$57.8K |
|
2286
Playtika
PLTK
$839M
| $50K | ﹤0.01% |
13,439
+3,137
| +30% | +$10.8K |
|
|
ACRE
2287
Ares Commercial Real Estate
ACRE
$254M
| $45.7K | ﹤0.01% |
10,156
-449
| -4% | -$2.22K |
|
2288
Fate Therapeutics
FATE
$297M
| $45.1K | ﹤0.01% |
16,696
+1,346
| +9% | +$2.49K |
|
2289
Organogenesis Holdings
ORGO
$220M
| $44.4K | ﹤0.01% |
+18,255
| New | +$44.6K |
|
2290
Cricut
CRCT
$1.16B
| $44.3K | ﹤0.01% |
+10,092
| New | +$43.2K |
|
|
SFIX
2291
Stitch Fix
SFIX
$407M
| $44K | ﹤0.01% |
+10,716
| New | +$39K |
|
|
ESPR
2292
DELISTED
Esperion Therapeutics
ESPR
| $43.6K | ﹤0.01% |
13,798
+956
| +7% | +$2.67K |
|
2293
Compass Therapeutics
CMPX
$429M
| $43.3K | ﹤0.01% |
19,792
+3,439
| +21% | +$10.2K |
|
2294
Inhibikase Therapeutics
IKT
$349M
| $43.2K | ﹤0.01% |
+21,293
| New | +$38.1K |
|
2295
Cerus
CERS
$522M
| $43K | ﹤0.01% |
14,741
+867
| +6% | +$2.1K |
|
2296
Sana Biotechnology
SANA
$1.15B
| $42.1K | ﹤0.01% |
12,066
-2,261
| -16% | -$7.28K |
|
|
BHR
2297
Braemar Hotels & Resorts
BHR
$130M
| $40.5K | ﹤0.01% |
18,755
+4,660
| +33% | +$11.2K |
|
2298
Anavex Life Sciences
AVXL
$265M
| $39.3K | ﹤0.01% |
+15,188
| New | +$44.9K |
|
2299
TH International
THCH
$43.2M
| $38.1K | ﹤0.01% |
19,937
| – | – |
|
2300
Akebia Therapeutics
AKBA
$270M
| $37.8K | ﹤0.01% |
+33,143
| New | +$39.5K |
|
Similar funds
Neuberger Berman Group's Q2 2026 Portfolio in Review
As of Q2 2026, Neuberger Berman Group held 2,421 positions worth $150B, up 14% from $131B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Neuberger Berman Group's Q2 2026 filing shows 260 new, 1,156 increased, 848 reduced and 81 closed positions. Its largest new stake was SpaceX: 2,127,228 shares worth $363M. The largest sale was Advanced Micro Devices, an estimated $428M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 25% a quarter earlier, followed by Financials and Industrials.
- Neuberger Berman Group's largest Q2 2026 buy was SpaceX: 2,127,228 shares worth $363M.
- Neuberger Berman Group added most to Amazon in Q2 2026, an estimated $463M increase.
- Neuberger Berman Group's biggest Q2 2026 reduction was Advanced Micro Devices, cutting an estimated $428M.
- Neuberger Berman Group fully exited Hologic in Q2 2026, selling an estimated $103M.
- Neuberger Berman Group's ten largest holdings make up 23% of its $150B portfolio in Q2 2026.
- Neuberger Berman Group opened 260 new positions and closed 81 in Q2 2026.
- Neuberger Berman Group's portfolio value rose 14% quarter-over-quarter to $150B.
Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.